An open-label study in healthy men to evaluate the risk of seminal fluid transmission of denosumab to pregnant partners.

Clinical trial considerations on male contraception and collection of pregnancy information from female partner: update. Clin Transl Med (2016) 1.39

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature (1999) 12.32

World Health Organization reference values for human semen characteristics. Hum Reprod Update (2009) 7.71

Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement (2001) 2.72

The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res (2014) 2.52

IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol (2011) 2.36

Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am J Reprod Immunol (1996) 1.79

Baseline dimensions of the human vagina. Hum Reprod (2006) 1.59

In vivo distribution of a vaginal gel: MRI evaluation of the effects of gel volume, time and simulated intercourse. Contraception (2004) 1.40

An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res B Dev Reprod Toxicol (2009) 1.28

Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol (2009) 1.19

Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data. Clin Ther (2012) 1.06

The optimal analysis of MRI data to quantify the distribution of a microbicide. Contraception (2005) 1.05

IgG subclass distribution in serum and various mucosal fluids of HIV type 1-infected subjects. AIDS Res Hum Retroviruses (2000) 0.99

Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. J Bone Miner Res (2003) 0.99

Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses. J Immunol (2007) 0.99

The transport of chemicals in semen. Birth Defects Res B Dev Reprod Toxicol (2005) 0.97

Reproductive toxicity of denosumab in cynomolgus monkeys. Reprod Toxicol (2013) 0.95

Materno-fetal immunoglobulin transfer and passive immunity during the first trimester of human pregnancy. Hum Reprod (1995) 0.92

Vaginal distribution of two volumes of the novel microbicide gel cellulose sulfate (2.5 and 3.5 mL). Contraception (2005) 0.90

Clinical trial considerations on male contraception and collection of pregnancy information from female partners. J Transl Med (2012) 0.89

Investigation of maternal and fetal exposure to an IgG2 monoclonal antibody following biweekly intravaginal administration to cynomolgus monkeys throughout pregnancy. Reprod Toxicol (2014) 0.88

Assessment of fetal exposure risk following seminal excretion of a therapeutic IgG4 (T-IgG4) monoclonal antibody using a rabbit model. Reprod Toxicol (2014) 0.83

Placental transfer of a fully human IgG2 monoclonal antibody in the cynomolgus monkey, rat, and rabbit: a comparative assessment from during organogenesis to late gestation. Birth Defects Res B Dev Reprod Toxicol (2014) 0.79

Infant cynomolgus monkeys exposed to denosumab in utero exhibit an osteoclast-poor osteopetrotic-like skeletal phenotype at birth and in the early postnatal period. Bone (2014) 0.79